NCT06025851View on ClinicalTrials.gov

Intravenous Doses of CM-101 as a Treatment for Medical Conditions Involving Inflammatory and Fibrotic Mechanisms in Healthy Male Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

July 24, 2017

Primary Completion Date

February 18, 2018

Study Completion Date

February 18, 2018

Conditions
Healthy
Interventions
DRUG

Anti-human CCL24 monoclonal antibody (CM-101)

Intravenous Infusion of Anti-human CCL24 monoclonal antibody (CM-101)

DRUG

Placebo

Placebo Comparator

Trial Locations (1)

Unknown

Tel Aviv Sourasky Medical Center, Tel Aviv

All Listed Sponsors
lead

ChemomAb Ltd.

INDUSTRY

NCT06025851 - Intravenous Doses of CM-101 as a Treatment for Medical Conditions Involving Inflammatory and Fibrotic Mechanisms in Healthy Male Subjects | Biotech Hunter | Biotech Hunter